542 related articles for article (PubMed ID: 15749931)
1. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion.
Nakamura K; Inaba M; Sugiura K; Yoshimura T; Kwon AH; Kamiyama Y; Ikehara S
Stem Cells; 2004; 22(2):125-34. PubMed ID: 14990852
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic intra-BM-BMT plus adult thymus transplantation from same donor has benefits for long-term survival even after sublethal irradiation or low-dose BM cell injection.
Nishida T; Hosaka N; Takaki T; Miyake T; Cui W; Inaba M; Kinoshita H; Matsuda T; Ikehara S
Bone Marrow Transplant; 2009 Jun; 43(11):829-37. PubMed ID: 19079314
[TBL] [Abstract][Full Text] [Related]
7. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
9. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
10. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
11. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
[TBL] [Abstract][Full Text] [Related]
12. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
13. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
14. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
15. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation.
Kaneda H; Adachi Y; Saito Y; Ikebukuro K; Machida H; Suzuki Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Wang J; Imamura H; Ikehara S
J Heart Lung Transplant; 2005 Sep; 24(9):1415-23. PubMed ID: 16143265
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
17. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
[TBL] [Abstract][Full Text] [Related]
18. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
19. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects.
Miyake T; Hosaka N; Cui W; Nishida T; Takaki T; Inaba M; Kamiyama Y; Ikehara S
Immunology; 2009 Apr; 126(4):552-64. PubMed ID: 18778285
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
